Mary D. Chamberlin, MD | Authors

HER2-Positive Breast Cancer: The Story Goes On

April 15, 2014

It will be critically important to await the longer-term DFS and OS results from the neoadjuvant studies, as well as the adjuvant studies evaluating dual HER2 blockade, prior to these approaches truly becoming the standard of care.